BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9510497)

  • 1. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
    Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
    Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
    Reed E; Gupta-Burt S; Litterst CL; Poirier MC
    Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
    Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
    Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
    Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
    Fisch MJ; Howard KL; Einhorn LH; Sledge GW
    Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
    Welters MJ; Braakhuis BJ; Jacobs-Bergmans AJ; Kegel A; Baan RA; van der Vijgh WJ; Fichtinger-Schepman AM
    Ann Oncol; 1999 Jan; 10(1):97-103. PubMed ID: 10076728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
    J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
    Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH
    Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.
    Boer H; Proost JH; Nuver J; Bunskoek S; Gietema JQ; Geubels BM; Altena R; Zwart N; Oosting SF; Vonk JM; Lefrandt JD; Uges DR; Meijer C; de Vries EG; Gietema JA
    Ann Oncol; 2015 Nov; 26(11):2305-10. PubMed ID: 26347114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
    Hospers GA; de Vries EG; Mulder NH
    Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin.
    Gelevert T; Messerschmidt J; Meinardi MT; Alt F; Gietema JA; Franke JP; Sleijfer DT; Uges DR
    Ther Drug Monit; 2001 Apr; 23(2):169-73. PubMed ID: 11294519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
    Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
    Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
    Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
    Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
    Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH
    Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.